Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support

At FDLI, both US FDA acting Commissioner Stephen Ostroff and BIO’s Kay Holcombe strike note of anticipating positive outcomes for FDA, despite current political and regulatory uncertainties. FDA has been through challenges before, and “we have come through them even stronger," Ostroff assures meeting.

More from US FDA

More from Agency Leadership